The group activities are organized around closely related axes that are supervised by senior researchers.
Our research programs focus i) on the characterization of anti-tumor T-cell responses in melanoma and colorectal carcinoma, as well as their regulation within the tumor microenvironment, both through immune checkpoints or activation of the tumor-cell inflammasome, and ii) on the characterization of relevant tumor-specific antigens, and the mechanisms leading to this specific expression, with the aim to identify new targets for immunotherapy in these solid tumors.
On a translational level, the objectives of our programs are to develop immunotherapy protocols in solid tumors (mainly with the adoptive transfer of effector T cells with optimized functions, associated or not with immune checkpoint inhibitors), and to identify early immune markers associated with clinical responses to immunotherapy treatments. Several projects from our group are conducted in the context of the LabEx IGO program, co-led by N. Labarriere (ImmunoGraft Oncology – http://www.labex-igo.com/).
Our research activities are organized around 3 interconnected axes, led by senior scientists:
Axis (1) led by N. Gervois
Immune intra-tumoral microenvironnement and regulation
Axis (2) led by F. Lang
Regulation of tumoral antigens expression
Axis (3) led by N. Labarrière et F. Lang
N. Labarriere DR2 (Inserm, 100%)
N. Gervois PU (Univ, 50%)
F. Lang PU (Univ, 50%)
C. Bossard PU-PH (Hospital, 50%)
A. Jarry CRCN (Inserm, 100%)
C. Rabu MCU (Univ, 50%)
H. Benlalam MCU (Univ, 50%)
R. Oger (Permanent AI Univ, 50%)
A. Fortun (Permanent AI Univ, 50%)
C. Deleine (Permanent TR Univ, 100%)
T. Beauvais (CDD, IE Hospital, 100%)
F. Briand (CDD, IE Inserm, 100%)
L. Bilonda Mutala
Rabu C, Rangan L, Florenceau L, Fortun A, Charpentier M, Dupré E, Paolini L, Beauvillain C, Dupel E, Latouche JB, Adotevi O, Labarrière N & Lang F. Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells, Oncoimmunol 2019 8:4, doi: 10.1080/2162402X.2018.1560919
Simon S, Wu Z, Cruard J, Vignard V, Fortun A, Khammari A, Dreno B, Lang F, Rulli SJ, Labarriere N. TCR Analyses of Two Vast and Shared Melanoma Antigen-Specific T Cell Repertoires: Common and Specific Features. Front Immunol. 2018 9:1962. doi: 10.3389/fimmu.2018.01962.
Jouand N, Bressollette-Bodin C, Gérard N, Giral M, Guérif P, Rodallec A, Oger R, Parrot T, Allard M, Cesbron-Gautier A, Gervois N, Charreau B. HCMV triggers frequent and persistent UL40-specific unconventional HLA-E-restricted CD8 T-cell responses with potential autologous and allogeneic peptide recognition. PLoS Pathog. 2018 14(4):e1007041. doi: 10.1371/journal.ppat.1007041.
Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy? Oncoimmunology. 2017 Sep 14;7(1):e1364828. doi: 10.1080/2162402X.2017.1364828. eCollection 2017. Review.
Simon S, Vignard V, Varey E, Parrot T, Knol AC, Khammari A, Gervois N, Lang F, Dreno B, Labarriere N. Emergence of High-Avidity Melan-A-Specific Clonotypes as a Reflection of Anti-PD-1 Clinical Efficacy. Cancer Res. 2017 77(24):7083-7093. doi: 10.1158/0008-5472.CAN-17-1856.
Jarry A, Malard F, Bou-Hanna C, Meurette G, Mohty M, Mosnier JF, Laboisse CL, Bossard C. Interferon-Alpha Promotes Th1 Response and Epithelial Apoptosis via Inflammasome Activation in Human Intestinal Mucosa. Cell Mol Gastroenterol Hepatol. 2016 Sep 20;3(1):72-81. doi: 10.1016/j.jcmgh.2016.09.007.
Parrot T, Oger R, Benlalam H, Raingeard de la Blétière D, Jouand N, Coutolleau A, Preisser L, Khammari A, Dréno B, Guardiola P, Delneste Y, Labarrière N, Gervois N. CD40L confers helper functions to human intra-melanoma class-I-restricted CD4(+)CD8(+) double positive T cells. Oncoimmunology. 2016 5(12):e1250991. doi: 10.1080/2162402X.2016.1250991.
Charpentier M, Croyal M, Carbonnelle D, Fortun A, Florenceau L, Rabu C, Krempf M, Labarrière N, Lang F. IRES-dependent translation of the long non coding RNA meloe in melanoma cells produces the most immunogenic MELOE antigens. Oncotarget. 2016 7(37):59704-59713. doi: 10.18632/oncotarget.10923.